Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12552788-B2

Patent

Publication Date

2026-02-17

Expiration Date


Abstract

Provided herein are lipidated imidazoquinoline compounds and compositions comprising such compounds. The lipidated imidazoquinoline compounds may be used as an adjuvant to enhance to immune response elicited by an antigen of interest. Accordingly, also provided herein are methods for enhancing the immune response of an antigen of interest in a subject, comprising administering to the subject an antigen of interest with a lipidated imidazoquinoline compound described herein in an immunogenic composition, or administering to the subject a composition comprising a lipidated imidazoquinoline compound described herein in combination with (e.g., prior to, concurrently, or subsequently) the administration of an immunogenic composition comprising an antigen of interest to the subject.

Core Innovation

The invention is directed to lipidated imidazoquinoline TLR7/8 agonist adjuvant compounds having a specified structure, including IMDQ-PEG-CHOL, wherein n is an integer from 10 to 200. The compound is provided as an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt, and functions as a TLR7/8 agonist adjuvant when formulated with an antigen of interest.

The invention further provides pharmaceutical and immunogenic compositions that include the compound together with a pharmaceutically acceptable carrier and an antigen of interest. Exemplary antigens explicitly include a SARS-CoV-2 spike protein ectodomain with RRAR-to-A and proline substitutions, trimerized using a T4 foldon trimerization domain, and optionally including a hexa-histidine tag or a flag tag.

The document also describes uses and methods for inducing, immunizing against, and preventing diseases associated with the antigen by concurrent or staggered co-administration of an IMDQ-PEG-CHOL pharmaceutical composition with an antigen immunogenic composition. It states that immune response metrics increase versus IMDQ or formulations lacking the adjuvant, including humoral and cellular immune response components, neutralizing antibodies, immune cell recruitment and activation, and activation of IFN and NF-kappaB, with reduced cytotoxicity.

Claims Coverage

The independent claims cover three inventive features: a defined lipidated imidazoquinoline compound structure with n from 10 to 200, pharmaceutical compositions including the compound and a pharmaceutically acceptable carrier, and immunogenic compositions comprising the compound with an antigen of interest, including specified SARS-CoV-2 spike ectodomain and influenza antigen formats.

Defined lipidated imidazoquinoline compound with n from 10 to 200

A compound having the following structure, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, wherein n is an integer from 10 to 200.

Pharmaceutical composition including compound and pharmaceutically acceptable carrier

A pharmaceutical composition including the compound and a pharmaceutically acceptable carrier.

Immunogenic composition including SARS-CoV-2 spike ectodomain with defined substitutions

An immunogenic composition including a SARS-CoV-2 antigen composed of a spike protein ectodomain with amino-acid substitutions at designated residues from GenBank accession MN908947.3, including an RRAR-to-A change at residues 682-685 and proline substitutions at residues 986-987.

Immunogenic composition using a T4 foldon trimerization domain

The immunogenic composition wherein the trimerization domain is a T4 foldon trimerization domain.

Immunogenic composition specifying an antigen tag

The immunogenic composition wherein a stated tag is either a hexa-histidine tag or a flag tag.

Immunogenic composition with trivalent or quadravalent inactivated influenza antigen

The immunogenic composition wherein the antigen of interest is a trivalent or quadravalent inactivated influenza virus composition.

Overall, the claim coverage centers on a lipidated imidazoquinoline compound structure with n in the range of 10 to 200, and on pharmaceutical and immunogenic compositions that combine the compound with a pharmaceutically acceptable carrier and antigen of interest, including a specifically engineered SARS-CoV-2 spike ectodomain with defined substitutions, T4 foldon trimerization, optional hexa-histidine/flag tagging, and trivalent or quadravalent inactivated influenza antigen formats.

Stated Advantages

Enhanced innate immune signaling as shown by increased IFN-beta and/or IFN-gamma and increased NF-kappaB activation versus matched formulations lacking the compound or using IMDQ.

Immune response metrics can increase versus IMDQ or formulations lacking the adjuvant.

Immune cell recruitment and immune cell activation are described as enhanced.

Humoral response components, ELISA/HI outcomes, and neutralizing antibodies are described as increased.

Reduced cytotoxicity is described, including via an MTT cytotoxicity assessment.

Concentration of immune activity in draining lymph nodes and increased immune activity in draining lymphoid tissue are described.

Prophylaxis and treatment potential is described, including preventing infection spread, reducing hospitalization, and symptom prevention or attenuation.

Potential sterilizing protection in mouse SARS-CoV-2 challenge models and improved influenza protection are described.

Documented Applications

Inducing, immunizing against, and preventing diseases associated with the antigen using concurrent or staggered co-administration of an IMDQ-PEG-CHOL pharmaceutical composition with an antigen immunogenic composition.

Immunogenic use with an antigen of interest that includes a SARS-CoV-2 antigen composed of a spike protein ectodomain engineered with RRAR-to-A and proline substitutions and presented in a trimerized form (T4 foldon), optionally with a hexa-histidine tag or a flag tag.

Immunogenic use with trivalent inactivated influenza virus composition or quadravalent inactivated influenza virus composition.

Immunogenic compositions formulated with an antigen of interest as a TLR7/8 agonist adjuvant, including applications involving prophylaxis and treatment for infection spread and hospitalization reduction.

Viral antigen application areas described in the document include SARS-CoV-2 and influenza, including mouse challenge model descriptions.

Cancer antigen application areas described include CEA, Ep-CAM, Her2/neu, mesothelin, Survivin, NY-ESO-1/LAGE-1, BRCA1/2, and Ras.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.